antipsychotic drugs inducing hyperprolactinemia
PreclinicalSmall molecule
antipsychotic drugs inducing hyperprolactinemia is one of 23 small molecule programs targeting Periodontitis. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
22
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
138 competitors in Periodontitis
#DrugCompanyPhaseTrials
1Peridex
DDexcel Pharma Technologies Ltd.
Phase 3
Acanya
PfizerPhase 3
Curcumin
Merck & Co.Phase 3
Bayer Aspirin
BayerPhase 2
Calcium Hydroxide
MMansoura University
Phase 3
Docosahexaenoic Acid
MMicelle BioPharma Inc
Phase 2
Calcium Intravenous Infsuion
MMansoura University
Phase 3
Minocycline Hcl
OOraPharma
Phase 3
Metapex
AAga Khan University
Phase 3
Boswellia
MMansoura University
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- FFayoum University